biostudies-literatureUnknown27(6)Kingo K<h4>Background</h4>The efficacy and safety of secukinumab up to week 52 in children and adolescents with moderate-to-severe chronic plaque psoriasis have been demonstrated previously (NCT03668613). Herein, we report the long-term efficacy, safety, and tolerability of secukinumab over a period of up to 208 weeks.<h4>Methods</h4>In this randomized open-label trial, patients (6 to < 18 years) were randomized 1:1 to receive low-dose (LD; N = 42) or high-dose (HD; N = 42) secukinumab stratified by weight (< 25 kg, 25 to < 50 kg, or ≥ 50 kg) and disease severity (moderate or severe). Patients weighing < 25 kg received 75 mg secukinumab (both LD and HD); 25 to < 50 kg received 75 mg (LD) or 150 mg (HD) secukinumab; and ≥ 50 kg received 150 mg (LD) or 300 mg (HD) secukinumab. The study assessed PsPaediatric drugs749-759https://www.ebi.ac.uk/biostudies/studies/S-EPMC12534278biostudies-literatureLong-Term Efficacy and Safety of Secukinumab in Children and Adolescents with Moderate-to-Severe Chronic Plaque Psoriasis: Four-Year Results of a Randomized, Phase III, Open-Label Trial.PMC12534278Bartonova JPapanastasiou PBallona RMagnolo NRavichandran SO'Doherty CBeissert SBansal AFan HVilla AVLazareva SKingo KMartin RfalseLong-Term Efficacy and Safety of Secukinumab in Children and Adolescents with Moderate-to-Severe Chronic Plaque Psoriasis: Four-Year Results of a Randomized, Phase III, Open-Label Trial.<h4>Background</h4>The efficacy and safety of secukinumab up to week 52 in children and adolescents with moderate-to-severe chronic plaque psoriasis have been demonstrated previously (NCT03668613). Herein, we report the long-term efficacy, safety, and tolerability of secukinumab over a period of up to 208 weeks.<h4>Methods</h4>In this randomized open-label trial, patients (6 to < 18 years) were randomized 1:1 to receive low-dose (LD; N = 42) or high-dose (HD; N = 42) secukinumab stratified by weight (< 25 kg, 25 to < 50 kg, or ≥ 50 kg) and disease severity (moderate or severe). Patients weighing < 25 kg received 75 mg secukinumab (both LD and HD); 25 to < 50 kg received 75 mg (LD) or 150 mg (HD) secukinumab; and ≥ 50 kg received 150 mg (LD) or 300 mg (HD) secukinumab. The study assessed Ps2025-01-01T00:00:00Z2025 Nov2026-07-15T11:55:55.26Z2026-07-04T03:12:11.512ZS-EPMC125342784087495410.1007/s40272-025-00715-4